Pharsight

Aricept generic

Aricept is a medication owned by Eisai Inc. Containing the active ingredient donepezil hydrochloride, Aricept was first authorized for market use on 23 July, 2010. Aricept is available in tablet form and is administered orally. Currently, Aricept holds one drug patent, none of which have expired.

When will Aricept generic be available?

The generic version of Aricept is expected to become available after 04 October, 2026. This date corresponds to the expiration of the patent (US8481565) titled 'Method for stabilizing anti-dementia drug', which expires on 2026-10-04. Hence, after this date, other pharmaceutical companies will have the opportunity to produce Aricept generic.

Aricept uses

Aricept is primarily used for the treatment of dementia related to Alzheimer's disease. The active ingredient, donepezil hydrochloride, works by increasing the amounts of certain substances in the brain that can help improve memory, awareness, and the ability to function.

Aricept patent expiration

Aricept currently holds one patent (US8481565) related to a unique method for stabilizing the anti-dementia drug. This patent is set to expire on 04 October, 2026 and could potentially delay the release of Aricept generic until after this date. Below is the detail of the patent:

Aricept dosage

Want to ask something?